StockData
Artelo Biosciences, Inc. logo

Artelo Biosciences, Inc. (ARTL) shareholders

ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.68−0.02 (-1.18%)

Close on Nov 17, 2026Market cap $1.13MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.3%
0M of 5M shares
Institutional holders
10
5 new, 5 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
235,8239.99%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ARTLValueChange% of portfolio
Jane Street Group, LLC7,3710.16%$74.30K+5,9180.00%
Geode Capital Management, LLC1,5410.03%$15.53KNew0.00%
StoneX Group Inc.1,3780.03%$14.69KNew0.00%
Vanguard Capital Management LLC1,1250.02%$11.34K–0.00%
Tower Research Capital LLC (TRC)9370.02%$9.45K+6230.00%
Vanguard Fiduciary Trust Co3490.01%$3.52K–0.00%
UBS Group AG3120.01%$3.14KNew0.00%
Rothschild Investment LLC00.00%$2–0.00%
Danske Bank A/S00.00%$1New0.00%
TD Waterhouse Canada Inc.00.00%$2New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026100M0.3%5 / 20 / 50M0M
Q1 2026110M0.1%7 / 10 / 50M0M
Q4 2025100M0.1%6 / 20 / 50M0M
Q3 202590M0.0%3 / 40 / 30M0M
Q2 202590M0.0%9 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Gregory D. GorgasPres, CEO, CFO, Treas & Secr, Director273,0765.94%Feb 2, 2026
Mark Edward SpringChief Financial Officer––Feb 2, 2026
Tamara A. FavoritoDirector––Jul 21, 2026
Robert Martin EmanueleDirector12,5000.27%Jul 21, 2026
Steven KellyDirector12,5000.27%Jul 21, 2026
Douglas BlayneyDirector12,5000.27%Jul 21, 2026
Gregory ReyesDirector––Jul 21, 2026
Connie MatsuiDirector56,6671.23%Jul 21, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Aug 12, 2022Buy+1,200$4.00$4.80K2,400
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Aug 11, 2022Buy+1,200$4.03$4.84K1,200
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Apr 16, 2021Buy+8,500$1.15$9.78K270,676
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
May 15, 2020Buy+4,200$1.21$5.08K262,176
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
May 4, 2020Buy+4,167$1.20$5.00K257,976
Connie Matsui
Director
May 4, 2020Buy+41,667$1.20$50.00K56,667
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Nov 4, 2019Buy+2,400$2.21$5.30K253,809
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Nov 1, 2019Buy+2,500$2.28$5.70K251,409
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Oct 31, 2019Buy+2,500$1.95$4.88K248,909
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Oct 30, 2019Buy+2,600$1.99$5.17K246,409
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Oct 15, 2019Buy+2,600$2.05$5.33K243,809
Gregory D. Gorgas
Pres, CEO, CFO, Treas & Secr, Director
Oct 11, 2019Buy+2,700$1.96$5.29K241,209
Peter Michael O'Brien
10% owner
Sep 4, 2019Other−17,500––7,500

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.58%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-20.2%
From 0M shares
Short volume, 20 days
40.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Artelo Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 72,699 shares on Sep 24, 2026 over the last 90 days.

See a number that looks wrong?